
|Videos|June 25, 2015
Phase IA Study of Atezolizumab in Urothelial Bladder Cancer
Author(s)Daniel Petrylak, MD
Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and of Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses a phase Ia study examining atezolizumab in patients with urothelial bladder cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
2
Teclistamab/Talquetamab Reduces Risk of Progression by 89% in R/R Multiple Myeloma
3
Advanced Renal Cell Carcinoma: Tailoring Second-Line Therapy After Prior Immunotherapy
4
Updated HARMONi Analysis Shows Consistent OS Benefit With Ivonescimab in EGFRm Lung Cancer
5






























